External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Krishna Institute of Medical Sciences / Equity Bottom-Up

Krishna Institute of Medical Sciences (KIMS IN)

<ul><li>Revenue In Line; Profitability Impacted by New Units: KIMS reported revenue broadly in line with our estimates, while EBITDA and PAT came in below expectations due to the initial ramp-up of new hospitals and the resultant operating deleverage. </li><li>Profitability was impacted by higher depreciation and interest costs associated with the new facilities introduced.</li><li>Reported revenue stood at 961 Cr, with margins at 21.2%, impacted by the addition of new units.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Revenue In Line; Profitability Impacted by New Units: KIMS reported revenue broadly in line with our estimates, while EBITDA and PAT came in below expectations due to the initial ramp-up of new hospitals and the resultant operating deleverage. Profitability was impacted by higher depreciation and interest costs associated with the new facilities introduced.Reported revenue stood at 961 Cr, with margins at 21.2%, impacted by the addition of new units.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues...